Mitiglinide for type 2 diabetes treatment

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 15, 2013, Pages 2133-2144

  Phillippe, Haley M ^a,b   Wargo, Kurt A ^a,b  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Meglitinide; Mitiglinide

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MITIGLINIDE; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; VALPROIC ACID; VOGLIBOSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; CHRONIC KIDNEY DISEASE; CONSTIPATION; DIET; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INSOMNIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; INSULIN TREATMENT; KINESIOTHERAPY; LIPID METABOLISM; LIVER MICROSOME; MEDICATION COMPLIANCE; MEDLINE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CARCINOMA; PANCREAS ISLET BETA CELL; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION; VOMITING; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; ISOINDOLES; TREATMENT OUTCOME;

EID: 84884585931     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.834048     Document Type: Review

References (28)

1. World Health Organization. Diabetes: what is diabetes?. Available from: www. who.int/mediacentre/factsheets/fs312/en/[Accessed 22 June 2013]
2. Centers for Disease Control and Prevention: national diabetes fact sheet. 2011. Available from: http://apps.nccd. cdc.gov/ddtstrs/FactSheet.aspx [Accessed 29 July 2013]
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;35:1364-79
4. Kaku K, Tanaka S, Origasa H, et al. Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. Endocr J 2009;56:657-64
5. Gao X; Mitiglinide Versus Nateglinide Comparison Study Group. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in china. J Int Med Res 2009;37:812-21
6. Chiasson J, Gomis R, Hanefeld M, et al. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to prevent non-insulin-dependent diabetes mellitus. Diabetes Care 1998;21:1720-5
7. Rodbard HW, Blonde L, Braithwaite SS, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13:3-68
8. Pratley RE, Foley JE, Dunning BE. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des 2001;7:1375-97
9. Novo Nordisk, Inc. Prandin (repaglinide) prescribing information. Princeton, NJ: 2010
10. Novartis Pharma Stein AG. Starlix (nateglinide) prescribing information. East Hanover, NJ: 2008
11. KISSEI R&D Pipeline. Available from: http://www.kissei.co.jp/e- contents/relation/pipeline.html [Accessed 22 June 2013]
12. Elixir Pharmaceuticals Product Pipeline. Available from: http://www.elixirpharm. com/product/index.html [Accessed 22 June 2013]
13. Abe M, Okada K, Maruyama T, et al. Combination therapy with mitiglinide and boglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11:169-76
14. Malaisse WJ. Mitiglinide: a rapid-and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother 2008;9:2691-8
15. Malaisse W. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003;2:401-14
16. Yu L, Lu S, Lin Y, Zeng S. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol 2007;73:1842-51
17. Abe M, Okada K, Maruyama T, et al. Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocr J 2010;57:579-86
18. Assaloni R, Da Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 2005;48:1919-24
19. Konya H, Miuchi M, Konishi K, et al. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. J Int Med Res 2009;37:1904-12
20. Kaku K, Tanaka S, Origasa H, et al. Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. Endocr J 2009;56:739-46
21. Kumashiro N, Yoshihara T, Kanazawa Y, et al. Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Endocr J 2007;54:163-6
22. Yoshihara T, Kumashiro N, Kanazawa Y, et al. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Endocr J 2006;53:67-72
23. Yamada S, Watanabe M, Funae O, et al. Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus. Intern Med 2007;46:1893-7
24. Li L, Yang M, Li Z, et al. Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial. Diabetes Obes Metab 2012;14:187-9
25. Kidney Disease: improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2012;3:1-150
26. Inoue M. Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2012;13:2257-68
27. Nakano T, Inoue I, Satoh K, et al. Treatment with glimepiride, but not mitiglinide and short-acting insulin, resists body weight and abdominal fat reduction under dietary energy restriction. J Atheroscler Thromb 2009;16:63-6
28. KISSEI Pharmaceutical Co. Available from: http://www.kissei.co.jp/di/ vcdb/pdf/if-gf08.pdf [Accessed 22 July 2013]